Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gataa, I. [1 ]
Mezquita, L. [1 ]
Auclin, E. [1 ]
Le Moulec, S. [2 ]
Alemany, P. [3 ]
Kossai, M. [3 ]
Masse, J. [4 ]
Caramella, C. [5 ]
Masip, J. Remon [1 ]
Lahmar, J. [1 ]
Ferrara, R. [1 ]
Gazzah, A. [1 ]
Soria, J-C. [6 ]
Planchard, D. [1 ]
Besse, B. [1 ]
Adam, J. [3 ]
机构：
[1] Gustave Roussy, Med Oncol Dept, Villejuif, France
[2] Inst Bergonie, Med Oncol, Bordeaux, France
[3] Gustave Roussy, Pathol Dept, Villejuif, France
[4] Bergonie, Pathol, Bordeaux, France
[5] Gustave Roussy, Radiol, Villejuif, France
[6] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
    Wang, X.
    Barrera, C.
    Lu, C.
    Velcheti, V.
    Madabhushi, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S393 - S393
  • [2] Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?
    Bremnes, Roy M.
    Donnem, Tom
    Busund, Lill-Tove
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (07)
  • [3] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
    Sankawa, Yuri
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
  • [4] Computer-extracted features relating to spatial arrangement of tumor infiltrating lymphocytes to predict response to nivolumab in non-small cell lung cancer (NSCLC).
    Barrera, Cristian
    Velu, Priya
    Bera, Kaustav
    Wang, Xiangxue
    Prasanna, Prateek
    Khunger, Monica
    Khunger, Arjun
    Velcheti, Vamsidhar
    Romero, Eduardo
    Madabhushi, Anant
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] The generation of tumor reactive lymphocytes in non-small cell lung cancer (NSCLC)
    Yannelli, JR
    Wroblewski, JM
    [J]. FASEB JOURNAL, 2002, 16 (04): : A667 - A667
  • [6] Outcomes of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) in A Regional Australian Population
    Kasherman, Lawrence
    Brungs, Daniel
    Bell, Graeme
    Glasgow, Amanda L.
    Tafreshi, Ali
    Clingan, Philip
    Aghmesheh, Morteza
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 145 - 146
  • [7] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality
    Merimsky, O.
    Shamai, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
  • [8] Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC)
    Federico, Lorenzo
    Haymaker, Cara
    Forget, Marie-Andree
    Vence, Luis
    Team, Icon
    Sharma, Padmanee
    Allison, James
    Fang, Bingliang
    Zhang, Jianjun
    Wagner, Heidi
    Bogatenkova, Elena
    Wistuba, Ignacio
    Sepesi, Boris
    Heymach, John
    Gibbons, Don Lynn
    Bernatchez, Chantale
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S630 - S631
  • [9] Impact of adding viagenpumatucel-L to nivolumab in non-small cell lung cancer (NSCLC) patients with low levels of tumour infiltrating lymphocytes
    Bahce, I.
    Hashemi, S.
    Fransen, M.
    Veltman, J.
    McDermott, L.
    Hutchins, J.
    Caldwell, C.
    Argyres, M.
    Long, B.
    Wolf, J.
    Thunnissen, E.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S883 - S883
  • [10] Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients
    Ronny Ben-Avi
    Ronit Farhi
    Alon Ben-Nun
    Marina Gorodner
    Eyal Greenberg
    Gal Markel
    Jacob Schachter
    Orit Itzhaki
    Michal J. Besser
    [J]. Cancer Immunology, Immunotherapy, 2018, 67 : 1221 - 1230
12345